Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Pharmaceutical Products — Clinical Trials Expense

Similar metrics at other companies

TransMedics Group, Inc. logo
TMDXProduct — Clinical Trial Expense
$0+100%
Sarepta Therapeutics, Inc. logo
SRPTAll Other Segments — Clinical Trial Expenses
$18.3M-44.8%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Development expenses
$756.6M-2.2%
MapLight Therapeutics, Inc. logo
MPLTClinical Trial — Research And Development Expense
$24.82M+1,180%
Glaukos logo
GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Clinical Research And Development Expense
$15.17M+60.9%
Bristol-Myers Squibb logo
BMYR&D
$2.65B+17.4%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$927.72M-19.9%
Enterprise value$1.44B-11.3%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept amph:ClinicalTrialsExpense.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's pharmaceutical products — clinical trials expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's pharmaceutical products — clinical trials expense?
Amphastar Pharmaceuticals (AMPH) reported pharmaceutical products — clinical trials expense of $1.55M in Q1 2026.
How has Amphastar Pharmaceuticals's pharmaceutical products — clinical trials expense changed year-over-year?
Amphastar Pharmaceuticals's pharmaceutical products — clinical trials expense increased by 63.7% year-over-year, from $948K to $1.55M.
What does pharmaceutical products — clinical trials expense mean?
This metric tracks the expenditures dedicated to conducting clinical research and development trials for new or existing pharmaceutical products. It reflects the company's commitment to innovation and the pipeline development necessary for long-term growth. High levels of spending indicate active investment in future product approvals and regulatory compliance.